American Society of Hematology

Schedule and Program for the ASH Summit on Emerging Immunotherapies

The following program for the 2018 ASH Summit on Emerging Immunotherapies for Hematologic Diseases is preliminary and subject to change.

8:00 a.m. – 7:00 p.m.
8:00 a.m. – 8:45 a.m.
Breakfast and Exhibits
11:05 a.m. – 11:35 a.m.
11:35 a.m. – 12:35 p.m.
12:35 p.m. – 2:35 p.m.
2:35 p.m. – 3:05 p.m.
3:05 p.m. – 3:20 p.m.
Networking Coffee Break
3:20 p.m. – 4:20 p.m.
Company Presentations
4:20 p.m. – 6:20 p.m.
6:20 p.m. – 6:50 p.m.
7:00 p.m. – 8:30 p.m.
Welcome and Networking Reception
8:00 a.m. – 4:00 p.m.
8:00 a.m. – 9:00 a.m.
Breakfast and Exhibits
9:20 a.m. – 10:35 a.m.
Breakout Sessions

Breakout I: Preparing the Garage: How to Prepare for the Commercialization of CAR T Cells

Catherine M. Bollard, MD, Children's National Medical Center

Adrian Gee, PhD, Baylor College of Medicine
Preparing the Garage in an Academic Setting

Kristin Baird, MD, U.S. Food and Drug Administration
FDA Requirements for Cell Manufacturing

Fabio Fachin, PhD, Torque Therapeutics, and Boro Dropulić, PhD, MBA, Lentigen Technology
GMP Perspective: What Does It Take to Move Cell-Based Immune Therapies to Commercialization?

Breakout II: Toxicity Management: Can We Make This Easier?

Sergio A. Giralt, MD, Memorial Sloan Kettering Cancer Center

Jennifer Holter Chakrabarty, MD, University of Oklahoma
Best Practices for Toxicity Management

James Kochenderfer, MD, National Cancer Institute, National Institutes of Health
Current Standards for Treatment and Prevention of Toxicities Related to CAR T Therapies

Bianca Santomasso, MD, PhD, Memorial Sloan Kettering Cancer Center
Neurotoxicity: Are There Vulnerable Populations: Very Old or Very Young?

Leslie Kean, MD, PhD, Seattle Children's Research Institute
Biomarkers and Toxicity
11:50 a.m. – 1:00 p.m.
1:00 p.m. – 1:50 p.m.
Company Presentations
1:50 p.m. – 2:50 p.m.
Reports From Breakout Sessions
3:05 p.m. – 3:50 p.m.
3:50 p.m. – 4:10 p.m.
Closing Remarks From Program Co-Chairs
back to top